Life science company BioDuro LLC revealed on Friday the election of Kent Payne, PhD as president of its CMC Global Solutions business.
Currently, Dr Payne is a board member for Goodwin Biotechnologies, a biological contract manufacturer, as well as board advisor for Vitruvias Therapeutics, a specialty generic pharmaceutical business.
Most recently, Dr Payne was employed as chief executive officer at Socorro Pharmaceuticals, a generic pharmaceutical company.
Previously, Dr Payne served as president Americas at Qualicaps Inc, principal consultant and partner at CoreFactor LLC and vice president/general manager at Catalent Pharma Solutions Inc. He has also held progressive leadership roles at Novartis, Monsanto and G.D. Searle.
Earlier, Dr Payne has held board and advisory roles at Life Science Institute Inc, a wholly-owned subsidiary of Mitsubishi Chemical Holdings, Technophar Inc, Qualicaps Inc and PDS Biotechnology (PDSB).
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets